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Hypoxia promotes stem cell phenotypes and poor
prognosis through epigenetic regulation of DICER
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Anil K. Sood6,12, Marianne Koritzinsky1,15,16 & Bradly G. Wouters1,2,4,16,17
MicroRNAs are small regulatory RNAs that post transcriptionally control gene expression.
Reduced expression of DICER, the enzyme involved in microRNA processing, is frequently
observed in cancer and is associated with poor clinical outcome in various malignancies. Yet,
the underlying mechanisms are not well understood. Here we identify tumour hypoxia as a
regulator of DICER expression in large cohorts of breast cancer patients. We show that DICER
expression is suppressed by hypoxia through an epigenetic mechanism that involves inhibi-
tion of oxygen-dependent H3K27me3 demethylases KDM6A/B and results in silencing of the
DICER promoter. Subsequently, reduced miRNA processing leads to derepression of the
miR-200 target ZEB1, stimulates the epithelial to mesenchymal transition and ultimately
results in the acquisition of stem cell phenotypes in human mammary epithelial cells. Our
study uncovers a previously unknown relationship between oxygen-sensitive epigenetic
regulators, miRNA biogenesis and tumour stem cell phenotypes that may underlie poor
outcome in breast cancer.
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C
ancer mortality is largely attributable to distant metastasis.
The mechanisms underlying the metastatic process are
complex and are part of a series of events that ultimately
result in the formation of macroscopic metastasis in distant
organs from cells with tumour initiating or ‘stem cell’ properties1.
Acquisition of stem cell and metastatic traits that enable this
process, and the conditions in tumours that stimulate it, are
poorly understood. However, many recent studies indicate that
some tumour cells are able to transition from an epithelial to
mesenchymal (EMT) phenotype through a process similar to
that which occurs in development. Acquisition of the
mesenchymal phenotype is associated with both increased
tumour-initiating properties and the ability to form metastases
in experimental models. However, in tumours this process
requires some degree of plasticity, as formation of a tumour at
a secondary metastatic site requires transition back to the
epithelial cell state (mesenchymal to epithelial transition).
Micro RNAs (miRNAs) are small regulatory RNAs that play an
important role in normal development and in disease by
regulating the expression of a vast number of target messenger
RNAs2. miRNA biogenesis begins with transcription of long
primary miRNAs (pri-miRNA) containing one or more hairpin
structures that are processed by the nuclear endonuclease
DROSHA, generating a 70-nucleotide stem loop known as the
precursor miRNA (pre-miRNA). The pre-miRNA is exported to
the cytoplasm by XPO5, and cleaved by DICER in a complex with
TRBP2 to generate a B22-nucleotide mature miRNA duplex.
One strand is loaded into the RNA-induced silencing complex,
which controls gene expression through sequence-speciﬁc
interactions with target mRNAs causing their degradation or
translational repression3. Several members of this miRNA
biogenesis pathway have been identiﬁed as haplo-insufﬁcient
tumour suppressors, including DICER itself, XPO5 and TRBP2
(refs 4–10). Using a variety of mouse models, these studies
indicate that partial suppression of miRNA biogenesis is sufﬁcient
to accelerate tumour development. Loss of one DICER allele in
mouse models results in a reduction in overall levels of mature
miRNA and increased lung and soft tissue sarcomas4,5. These
studies extend earlier clinical ﬁndings, demonstrating that
miRNA levels are frequently reduced in tumours6. It is not
clear how a reduction in miRNA biogenesis promotes cancer and
whether loss of one or more speciﬁc miRNAs underlies this effect.
However, miRNA has been hypothesized to confer ‘robustness’ to
biological processes including stabilizing differentiated cell
states11. In patients, low levels of DICER in breast, ovarian and
other cancers are associated with aggressive, invasive disease,
distant recurrence and poor overall survival12–14. In several
model systems, DICER repression has also been shown to
stimulate metastasis7,10.
In addition to monoallelic loss in cancer5, several mechanisms
have been described as potential regulators of DICER including
the transcription factors MITF15 and Tap63 (ref. 10) and miR-
103/107 (ref. 7). DICER expression has also been reported to be
inhibited by hypoxia through an unknown mechanism16.
Hypoxia is a common feature of tumours strongly associated
with poor prognosis in multiple sites, including breast
cancer17–19. Clinical studies show a strong association between
hypoxia and distant metastasis or relapse19–24. Laboratory data
support a direct role for hypoxia in driving metastasis, including
in vivo studies with cell line-derived25,26, and more recently,
patient-derived xenografts grown in the orthotopic site. Hypoxia
has been suggested to promote stemness in both normal tissues
and tumours27–32. However, the mechanisms driving this
aggressive phenotype are poorly understood.
In this study we have identiﬁed a new mechanism linking
hypoxia, reduced miRNA biogenesis and acquisition of
phenotypes associated with poor outcome. We show that tumour
hypoxia is associated with reduced DICER expression in large
cohorts of breast cancer patients and identify an epigenetic
mechanism that suppresses DICER transcription through inhibi-
tion of oxygen-dependent H3K27me3 demethylases KDM6A/B.
In breast cancer, reduced expression of DICER leads to a selective
decrease in processing of the miR-200 family and consequently to
derepression of ZEB1 and activation of the EMT and associated
stem cell phenotypes.
Results
Reduced DICER expression in hypoxic human breast cancers.
Both experimental and clinical data have demonstrated a strong
correlation between hypoxia and more aggressive disease,
including phenotypes recently linked to DICER suppression, such
as stemness33 and metastasis18,25. We therefore examined the
association between DICER expression, DICER copy number and
hypoxia in breast cancer. We stratiﬁed breast cancer patients
from two data sets (METABRIC34 and The Cancer Genome Atlas
(TCGA)35) having normal DICER copy number by the amount of
hypoxia as determined using the validated Winter hypoxia
signature36 (Fig. 1a and Supplementary Fig. 1a). The median
RNA expression of 99 hypoxia associated genes in the Winter
signature is an independent prognostic factor in head and neck
squamous cell carcinoma and breast cancer series. In both data
sets, patients with the largest hypoxic fraction exhibited the
lowest DICER mRNA expression (Fig. 1a and Supplementary
Fig. 1a). A signiﬁcant inverse correlation between hypoxia and
DICER expression was found for the TCGA, METABRIC, Harris
and 14 out of 18 smaller breast cancer gene expression studies
(Fig. 1b and Supplementary Table 1). A pooled data set,
consisting of 19 studies with long-term clinical follow-up, also
demonstrated a highly signiﬁcant (P¼ 5.80 10 13) inverse
correlation between DICER and hypoxia. Interestingly, in both
the pooled and METABRIC data sets, low levels of DICER and
high levels of hypoxia were associated with poor outcome (Fig. 1c
and Supplementary Figs 2 and 3). Notably, the reduction in
DICER expression in the most hypoxic quartile was reduced to
levels similar to that in theB5% of tumours that had monoallelic
loss of DICER. These data suggest that hypoxia is a key
contributor to DICER expression and is responsible for reduced
DICER levels in signiﬁcantly more patients than genetic loss. We
conﬁrmed that hypoxia suppresses DICER at both the mRNA
and protein level in a panel of breast cancer (MCF7, MDA-MB-
468, MDA-MB-231, SUM149 and HCC1954), normal (MCF10A)
or transformed (HMLER) mammary epithelial cell lines after
exposure to oxygen levels commonly found in human tumours
(o0.02 to 1.0% O2) (Fig. 1d–f and Supplementary Fig. 4).
Hypoxic suppression varied from 26% to 74% at the mRNA level
and 16% to 84% at the protein level over a period of 24–48 h of
hypoxia. DICER repression in hypoxia was not associated with
any particular breast cancer subtype in either the cell lines or in
the breast cancer clinical data sets (Supplementary Figs 2 and 3,
and Supplementary Table 1).
In addition to monoallelic loss in cancer, several mechanisms
have been implicated in DICER regulation. These include the
transcription factors MITF15 and Tap63 (ref. 10), which induce
DICER, miR-103/107, which repress DICER7, and a Von Hippel-
Lindau (VHL)-dependent mechanism affecting DICER protein
stability16. We examined each of these and found that none could
explain suppression of DICER by hypoxia in breast cancer.
Reporter constructs containing 2.5 kb of the DICER promoter
(with or without mutations in the MITF E-box elements) showed
no regulation by hypoxia (Supplementary Fig. 5a,b). Similarly, no
increase in miR-103/107 and no decrease in DICER transcript or
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protein stability were observed during hypoxia (Supplementary
Fig. 5c–f). We also observed no signiﬁcant difference in DICER
repression in cell lines isogenic for VHL (Supplementary Fig. 5g).
Importantly, MITF, Tap63 and miR-103/107 also showed weak or
no correlation with DICER expression in breast cancer patients in
the TCGA and METABRIC data sets (Supplementary Fig. 1b–h).
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Figure 1 | Impaired DICER expression in hypoxic human breast cancers. (a) DICER mRNA abundance in breast cancer patients fromMETABRIC stratiﬁed
by DICER copy number and hypoxic fraction as determined with the Winter hypoxia metagene. P-values obtained with Wilcoxon rank sum test. (b) Inverse
correlation between DICER mRNA abundance and hypoxia score. P-values obtained with Spearman’s correlation. (c) Kaplan–Meier survival curves for
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P-values obtained with one-way analysis of variance (ANOVA), Bonferroni’s post-hoc test. (e) Representative western blottings were performed with
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normalized for tubulin signal (n¼ 3). Error bars represent s.e.m. P-values obtained with one-way ANOVA, Bonferroni’s post-hoc test. *Po0.05, **Po0.01,
***Po0.001.
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DICER is epigenetically regulated during hypoxia. The lack of
regulation of the DICER reporter construct (Supplementary
Fig. 5a,b) during hypoxia was surprising. To directly test whether
transcription of the endogenous DICER locus was affected, we
measured changes in de novo transcription during hypoxia by
pulse-labelling RNA. These experiments demonstrated that
DICER transcription decreased 40% to 50% during hypoxia
(Fig. 2a), whereas the HIF1 target gene carbonic anhydrase-9
(CA9) increased 20-fold (Supplementary Fig. 7a). Transcriptional
suppression of DICER was not dependent on known hypoxia
response pathways, including either the HIF (hypoxia-inducible
factor) pathway (as reported previously16) or the PERK/ATF4
arm of the unfolded protein response (Supplementary Fig. 6a–e).
DICER repression occurred normally in both HIF1a knockout
cells and in multiple lines where HIF1a was depleted by RNA
interference (Supplementary Fig. 6a–c). In addition, hypoxic
downregulation of DICER did not affect HIF regulation in breast
cancer cell lines, which has been previously reported in other cell
types16 (Supplementary Fig. 6f).
Although HIF1 was not required for DICER suppression
during hypoxia, we found that agents that stabilize HIF by
inhibiting the HIF prolyl-hydroxylases (EGLN1/2/3) did cause
DICER suppression. Deferoxamine (DFO), cobalt chloride
(CoCl2) and dimethyloxalylglycine (DMOG) at concentrations
sufﬁcient to activate transcription of HIF1 target genes (for
example, CA9—Supplementary Fig. 7b) all resulted in a
signiﬁcant reduction in DICER at the mRNA and protein level
(Fig. 2b,d). DFO and CoCl2 stabilize HIF by chelating or
competing with iron [Fe(II)], whereas DMOG does so by
competitive inhibition of 2-oxogluterate, which in addition to
oxygen, are required co-factors for the HIF prolyl-hydroxylases
that mediate HIF stability. However, similar to hypoxia,
treatment with DFO, CoCl2 and DMOG also caused DICER
repression in HIF1a knockout cells (Fig. 2c).
As hypoxia, DFO, CoCl2 and DMOG all inﬂuenced DICER
expression in a HIF1a-independent manner, we hypothesized
that DICER was regulated through inhibition of alternative iron,
oxygen and 2-oxogluterate-dependent enzymes, such as the
Jumonji-domain containing hydroxylases KDM6A and
KDM6B37 that regulate epigenetic silencing through removal of
repressive histone 3 lysine 27 trimethylation (H3K27me3)
marks38. Indeed, inhibition of all three required cofactors of the
KDM6A/B enzymes by hypoxia, DFO, CoCl2 and DMOG
resulted in an increase in total H3K27me3 in multiple cell types
(Fig. 2d and Supplementary Fig. 7c). More importantly,
H3K27me3 chromatin immunoprecipitation followed by
sequencing (ChIP-seq) demonstrated that hypoxic exposure for
as short as 8 h led to an increase in repressive H3K27me3 marks
in the DICER promoter region (Supplementary Fig. 7d).
Enrichment in H3K27me3 at the DICER promoter during
hypoxia was conﬁrmed using conventional ChIP–quantitative
PCR (qPCR) in MCF7 (eightfold enrichment versus hypoxic IgG
control) and HMLER (ﬁvefold enrichment versus hypoxic IgG
control) cell lines (Fig. 2e). In both cell lines, this translated into
an approximate doubling of H3K27me3 as compared with levels
under normoxia. Furthermore, ChIP–qPCR analysis using
speciﬁc antibodies against the H3K27 methyltransferase EZH2
(writer) and the oxygen-dependent H3K27me3 demethylases
KDM6A and KDM6B (erasers) revealed signiﬁcant enrichment
over IgG controls at the DICER promoter for each respective
enzyme, with no signiﬁcant difference in enrichment between
normoxic and hypoxic conditions (Fig. 2f). Consistent with a role
for epigenetic regulation of DICER, knockdown of KDM6A or
KDM6B resulted in reduced DICER expression (Fig. 2g and
Supplementary Fig. 7e–g). Similarly, inhibition of KDM6A/B with
the inhibitor GSK-J4 at concentrations that increased overall
levels of H3K27me3 by 1.3-fold caused a 23% and 50% decrease
in DICER expression in MCF7 and HMLER cells, respectively
(Fig. 2h,i and Supplementary Fig. 7h,i) without affecting HIF
activity (Supplementary Fig. 7h). Conversely, knockdown of
EZH2 resulted in a signiﬁcant increase in DICER expression and
was able to largely prevent DICER repression during hypoxia
(Fig. 2j and Supplementary Fig. 7j). Similarly, inhibition of EZH2
using UNC1999 and GSK343 at levels that caused decreases in
global H3K27me3 levels by 50%–70% (Fig. 2l and Supplementary
Fig. 7k) also increased DICER to levels comparable with EZH2
knockdown (Fig. 2k and Supplementary Fig. 7l). Together, these
data indicate that basal expression of DICER is regulated by
dynamic and opposing activities of KDM6A/B and EZH2, which
are both constitutively present at the DICER locus, and that
suppression of KDM6A/B activity under hypoxia is sufﬁcient to
increase H3K27me3 in an EZH2-dependent manner and suppress
DICER transcription.
Hypoxia causes an miRNA processing defect. To examine the
consequences of DICER suppression, we created MCF7 and
HMLER breast cancer cell lines with stable knockdown of DICER
and assessed changes in levels of mature miRNA. Suppression of
DICER to B30% resulted in a widespread reduction in mature
miRNA for the majority of miRNA species (Fig. 3a,b and
Supplementary Fig. 8a). Hypoxia also led to an analogous
impairment in the processing of exogenously introduced short
hairpin (shRNA) (Supplementary Fig. 8b). Short interfering RNA
(siRNA) and shRNA targeting HIF1a showed similar efﬁciency
under aerobic conditions, but under hypoxia HIF1a shRNA,
Figure 2 | Epigenetic silencing of DICER promoter in response to hypoxia. (a) Total (Tot) and nascent (Nas) DICER mRNA expression during hypoxia in
MCF7 and HMLER cell lines was determined using quantitative reverse transcriptase–PCR (qRT–PCR) with RPL13A as control (n¼4). (b) Indicated
breast cancer cell lines (n¼ 3) or (c) HIF1a-null mouse embryonic ﬁbrobasts (MEFs) (n¼4) were exposed to 500mM iron chelator DFO, 250mM
antagonist CoCl2 or 500 mM DMOG for 24 h. DICER mRNA expression was determined using qRT–PCR with RPL13A or 18S as control. (d) Western blot
analysis of MCF7 cell extracts prepared after 24 h exposure to 0.2% O2, 500mM DFO, 250mM CoCl2 or 500mM DMOG with antibodies speciﬁc for
DICER, CA9 and H3K27me3. Tubulin and H3 serve as respective loading controls. Representative blot (right) and densitometric analysis of western
blottings from four independent experiments (left). (e) Validation of the enrichment in H3K27me at the DICER promoter was done using ChIP analysis of
H3K27me3 mark in combination with qRT–PCR analysis in MCF7 and HMLER cells during normoxia (N) or hypoxia (H). Fold-enrichment shown over
control IgG (n¼ 3). (f) Enrichment of EZH2, KDM6A or KDM6B at the DICER promoter was done using ChIP analysis of each enzyme in combination with
qRT–PCR analysis in MCF7 cells during normoxia (N) and hypoxia (H) (n¼ 3). (g,h) qRT–PCR analysis of DICER expression with RPL13A as control
in MCF7 cells (g) bearing shRNAs against KDM6A/B (n¼ 3) or (h) treated with 10mM KDM6A/B inhibitor GSK-J4 24h (n¼ 3). (i) Representative blot
(top) and quantiﬁcation of global H3K27me3 (bottom) after GSK-J4 treatment in h. DICER mRNA expression in MCF7 cells (j) transiently transfected
with siRNA directed against EZH2 during aerobic and hypoxic conditions (n¼4) or (k) treated with 5 mM EZH2 inhibitor UNC1999 or GSK343
for 48 h (n¼ 3). (l) Representative western blotting (top) and quantiﬁcation of global H3K27me3 levels (bottom) after EZH2 inhibition in k. Error bars
represent s.e.m. P-values obtained with Student’s t-test or one-way analysis of variance, Bonferroni’s post-hoc test. *Po0.05, **Po0.01, ***Po0.001.
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which requires DICER processing, was signiﬁcantly less efﬁcient.
Under hypoxia, HIF1a siRNA reduced the HIF target gene
CA9 by B50%, whereas HIF1a shRNA failed to prevent CA9
induction.
Sensitivity to DICER knockdown varied among different
miRNA and the ﬁve members of the miR-200 family
(miR-200a, miR-200b, miR-429, miR-200c and miR-141) were
among the most strongly repressed in both lines (Fig. 3b and
Supplementary Fig. 8a). Similarly, the miR-200a/b/429 cluster
was among the most strongly repressed miRNAs in response
to hypoxia (Fig. 3c). We conﬁrmed that both hypoxia and
DICER knockdown led to a substantial defect in the processing of
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miR-200 family precursors (pri-miRNAs) into mature miRNAs.
The ratio of mature to pri-miRNA, an indicator of DICER
activity, dropped substantially in response to both DICER
knockdown and hypoxia in MCF7, HMLER and SUM149 cells
(Fig. 3d–f and Supplementary Fig. 8c). Furthermore, the
reduction in DICER caused by inhibition of KDM6A/B using
GSK-J4 also resulted in a decrease in miR-200a/b/429 processing
similar to that during hypoxia or DICER knockdown (Fig. 3d).
Conversely, inhibition of EZH2 using UNC1999, which increased
DICER expression, increased miR-200a/b/429 processing
(Fig. 3d). Importantly, transient overexpression of DICER during
hypoxia increased miR-200a/b/429 processing to near basal levels,
demonstrating that these effects on miRNA processing under
hypoxia are due to its effects on DICER (Fig. 3d,f and
Supplementary Fig. 8d).
Despite the defect in miRNA processing caused by DICER
repression, some mature miRNAs increased during hypoxia,
including the widely reported hypoxia-inducible miR-210.
However, in this case the increase is due entirely to a
transcriptional effect (Supplementary Fig. 8e,f and Fig. 3g,h).
The processing of miR-210 mediated by DICER is reduced under
hypoxia, but this effect is smaller than the overall transcriptional
increase, resulting in increased mature levels of the miRNA.
Hypoxia stimulates EMT and CSC associated properties. The
miR-200 family is implicated in regulation of the ZEB1 and ZEB2
transcription factors, which repress E-cadherin and stimulate the
EMT39. DICER knockdown has previously been implicated in
promoting the EMT and metastasis through the miR-200 family7,
and miR-200b repression and ZEB1 induction during hypoxia has
been reported40,41. We hypothesized that DICER suppression
during hypoxia may similarly regulate the EMT and perhaps
underlie the known association of tumour hypoxia with
metastasis, stemness and aggressive disease. Indeed, DICER
repression in response to hypoxia or knockdown resulted in
enhanced expression of ZEB1, loss of epithelial marker expression
(E-cadherin) and increased expression of mesenchymal markers
(N-cadherin and Vimentin) (Fig. 4a–c). The transcription factor
TWIST, previously implicated in hypoxia-induced EMT and
metastasis42, remained unchanged, as did the transcription factor
SNAIL (Supplementary Fig. 9a,b). The hypoxia- and DICER
knockdown-induced EMT is mechanistically distinct from the
classical EMT inducer transforming growth factor-b1 (TGFb1),
which was associated with increased expression of TWIST and
SNAIL, but caused no change in DICER expression or miRNA
biogenesis (Supplementary Fig. 9c–e).
In breast cancer, the EMT has been linked to acquisition of
stem cell phenotypes, including expression of cell surface antigens
associated with human breast stem cells (CD44high CD24low),
increased mammosphere formation and increased tumour
initiation capacity43–45. In HMLER cells, hypoxic exposure led
to an increase in the frequency of CD44high CD24low cells from
11.5% to 73.7% (Fig. 4d,e), comparable to levels observed
following exposure to TGFb1 (Supplementary Fig. 9e) or
reported following forced exposure of SNAIL or TWIST43.
A similar increase in the fraction of CD44highCD24low cells
occurred following DICER knockdown alone (76.6% and 81.5%
versus 14.1%) (Fig. 4d,e). Both hypoxic exposure and DICER
knockdown resulted in a greater than ﬁvefold increase in
mammosphere formation similar to that observed following
TGFb1 exposure (Fig. 4f). Importantly, hypoxia is similarly able
to inﬂuence H3K27me3, DICER, EMT and stem cell phenotypes
in vivo. We established HMLER xenografts and examined the
spatial relationship between hypoxia, H3K27me3 and CD44 using
multi-ﬂuorescence immunohistochemistry. As shown in Fig. 4g,h,
tumour hypoxia in vivo (as assessed by EF5) is strongly associated
with increased expression of the stem cell marker CD44
(Fig. 4g,h). Hypoxic tumour areas also show increased overall
levels of H3K27me3, with discernable gradients in expression
away from hypoxic areas (Fig. 4i). Furthermore, we assessed
DICER, ZEB1 and E-cadherin expression in vivo using a panel of
breast cancer xenografts and found that DICER and E-cadherin
were inversely correlated with the endogenous hypoxia marker
CA9, whereas ZEB1 showed a positive correlation with CA9
(Supplementary Fig. 9f).
Finally, we tested directly if hypoxia- and DICER knockdown-
induced EMT and acquisition of stem cell phenotypes is
dependent on loss of mature miR-200 levels. DICER over-
expression during hypoxia, which rescued the defect in miR-200
processing (Fig. 3d), also prevented increased expression of ZEB1
(Supplementary Fig. 9g). Furthermore, overexpression of miR-
200b alone prevented increased expression of ZEB1 and loss of
E-cadherin during hypoxia, without affecting DICER repression
and the defect in miRNA biogenesis (Fig. 5a,b). miR-200b
overexpression during hypoxia also prevented the increase in the
CD44highCD24low population and mammosphere formation
(Fig. 5c–e). Together, these demonstrate that hypoxic suppression
of DICER causes an EMT-driven acquisition of stem cell
properties in breast cancer through a reduction in the biogenesis
of mature miR-200 family members (Fig. 5f).
Discussion
Our study demonstrates that hypoxia in the tumour microenvir-
onment is a contributor to DICER expression and repression of
miRNA biogenesis. In large independent cohorts of breast cancer
patients, the association between hypoxia and DICER is stronger
than any previously reported regulator of DICER, and the number
of patients affected by this mechanism exceeds those harbouring
monoallelic loss. This analysis also indicates that DICER
suppression may underlie part of the known association of
hypoxia with metastasis and poor outcome, although hypoxia
remains a better discriminator than DICER in breast cancer
patients. This is perhaps not surprising given that hypoxia
inﬂuences other important biological processes, including angio-
genesis, altered metabolism and chromosomal instability. The
changes in histone methylation and DICER expression are
relatively small (approximately twofold) in response to hypoxia
or inhibition of EZH2 and KDM6A/B. Previous studies unam-
biguously identiﬁed DICER as a haploinsufﬁcient tumour suppres-
sor and an important driver of tumorigenesis under conditions of
o50% repression4,5. Our study is consistent with these earlier
reports and demonstrates that relatively small changes in DICER
expression during hypoxia underlie functional changes in miRNA
biogenesis, EMT and properties associated with stemness.
Interestingly, Rupaimoole et al. have demonstrated that hypoxia
causes additional suppression of miRNA biogenesis through
silencing of DROSHA46 and that the combined defect in miRNA
biogenesis resulting from DICER and DROSHA suppression leads
to increased metastasis in ovarian cancer. The coordinated
suppression of these two key enzymes required for miRNA
biogenesis as well as hypoxia-dependent suppression of AGO2
(ref. 47) suggests a particularly important and broad role for oxygen
in the regulation of miRNA levels. The consequences of such
regulation are likely to be different in speciﬁc tissues and cancer
types, depending on the expression of different miRNAs. In breast
cancer, we show that selective sensitivity of the miR-200 family to
loss of DICER plays a dominant role in regulation of EMT and
cancer stem cell phenotypes, which may underlie the known
association of hypoxia with aggressive disease in breast and other
cancer types12–14,17–18.
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Previous studies have reported multiple mechanisms of
DICER regulation, which can occur at the level of transcription
through MITF15 and Tap63 (ref. 10), mRNA stability through
miR-103/107, as well as at the protein level in a VHL-dependent
manner16. Our study reveals that DICER transcription is also
regulated dynamically by acquisition or loss of the repressive
H3K27me3 polycomb mark that is typically associated with gene
silencing38. This mark is also found on promoters of so-called
‘poised’ genes expressed at low levels in embryonic stem cells
where it is often associated with co-occurrence of the activating
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H3K4 mark48. Several previous studies have indicated that the
balance between writing (EZH2) and erasing (KDM6A/B)
H3K27me3 marks within the genome can play an important
role in cancer49,50. This is supported by the ﬁnding that EZH2 is
frequently overexpressed or activated in cancer51–53, and
associated with increased metastasis54. Conversely, the
H3K27me3 demethylase KDM6A is frequently mutated in
human cancers55,56 and KDM6B expression is decreased in
subsets of human cancers57,58. Our study identiﬁes DICER as an
important integrator of EZH2 methyltransferase and KDM6A/B
demethylase activity. We showed that EZH2 and KDM6A/B are
present at the DICER locus, and that inhibition of these enzymes
can cause acute changes in the levels of H3K27me3, DICER
expression and DICER activity. The hydroxylase activity of
KDM6A/B requires molecular oxygen, 2-oxogluterate and Fe(II)
to demethylate H3K27me3. Correspondingly, we found that
hypoxia, or depletion/competition of the other co-factors with
DFO, CoCl2 or DMOG, all suppress DICER. To our knowledge,
this is the ﬁrst such example of a gene whose expression is
dynamically regulated at the epigenetic level by the availability of
metabolic enzymatic co-factors. As the basal levels of H3K27me3
are inﬂuenced by both EZH2 and KDM6A/B activities, we
expect that additional metabolic co-factors that regulate their
activity including methyl donation (EZH2) or 2-oxogluterate
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Figure 5 | Hypoxia stimulates cancer stem cell-associated phenotypes in a miR-200b-dependent manner. HMLER cells overexpressing miR-200b
or green ﬂuorescent protein (GFP) (n¼ 3) grown for 7 days under 1% O2 or control conditions. (a,b) quantitative reverse transcriptase–PCR analysis
was performed to measure (a) mature miR-200b levels and (b) DICER, ZEB1 and E-cadherin mRNA levels where RPL13A served as control (n¼ 3).
(c) Representative FACS analysis using antibodies speciﬁc for CD44 and CD24. (d) Quantiﬁcation of the percentage of cells with CD44 highCD24low for
three independent experiments. (e) Sphere formation assay, number spheres formed per 500 cells plotted (n¼ 3). (f) Model of hypoxia-mediated
EMT and stemness. Error bars represent s.e.m. P-values obtained with Student’s t-test. *Po0.05, **Po0.01.
Figure 4 | DICER repression promotes cancer stem cell-associated phenotypes by reduced miR-200 expression during hypoxia. (a) HMLER cells were
grown for 7 days under 1% O2. RNA was extracted and used to determine DICER mRNA levels by quantitative reverse transcriptase–PCR analysis.
Expression of epithelial and mesenchymal-associated genes was assessed simultaneously. RPL13A served as control (n¼ 3). (b) Similar analysis as in a was
performed on HMLER cells transduced with two independent shRNA constructs targeting DICER (n¼ 3). (c) HMLER protein extracts were subjected to
western blot analysis of DICER, E-cadherin, Vimentin and eIF4E as loading control. (d) Representative FACS analysis of HMLER cells using antibodies
speciﬁc for CD44 and CD24. (e) Quantiﬁcation of the percentage of cells with CD44highCD24low for three independent experiments. (f) Sphere formation
assay, number of spheres formed per 500 cells plotted (n¼ 3). (g) Representative image of whole tumour (top) and 25 region (bottom) of CD44
(green), EF5 (red) and DAPI (blue) staining in HMLER orthotopic xenograft. (h) Mean CD44 intensity in hypoxic (EF5 negative) versus non-hypoxic (EF5
positive) tumour regions of HMLER xenografts (n¼8 mice). (i) Representative image of whole tumour (top) and 25 region (bottom) of H3K27me3
(green), EF5 (red) and DAPI (blue) staining in HMLER orthotopic xenograft. N indicates regions of tumour necrosis. Scale bar, 100mm. Error bars represent
s.e.m. P-values obtained with Student’s t-test or one-way analysis of variance, Bonferroni’s post-hoc test. *Po0.05, **Po0.01, ***Po0.001.
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(KDM6A/B) will similarly inﬂuence DICER H3K27me3 levels
and its expression.
In contrast to genetic alteration of EZH2 and/or KDM6A/B,
hypoxia-driven changes in the epigenetic state of DICER enables
transient changes in cell phenotype in response to the local
tumour microenvironment. In breast cancer, our ﬁndings
demonstrate that suppression of DICER during hypoxia is
sufﬁcient to reduce miR-200 levels and enable cells to undergo
an EMT and acquire stem cell properties. The fact that this occurs
at the epigenetic level in an EZH2-dependent manner is
consistent with a recent report that implicates EZH2 in
controlling the EMT through epigenetic reprogramming59, but
provides a potential mechanism for cells to retain plasticity and
restore DICER and miR-200 levels when oxygen becomes
available. Cancer cells need to undergo the reverse process,
mesenchymal to epithelial transition, to ensure successful
colonization and metastatic outgrowth60,61. We speculate that
the clinical importance of hypoxia in driving metastasis and poor
outcome is linked to this ability to transiently inﬂuence cell
phenotype via DICER expression and miRNA biogenesis.
Finally, our results provide new potential therapeutic oppor-
tunities for targeting hypoxia and its inﬂuence on poor outcome
in cancer. Hypoxia has been demonstrated to inﬂuence patient
outcome, both through its ability to promote metastatic growth of
disseminated stem cells and for regrowth of tumours following
treatment. Hypoxic cells are intrinsically resistant to radiation
and other forms of chemotherapy and small numbers of these
cells can ‘re-seed’ the tumour, enabling regrowth following
therapy. Hypoxic tumour cells also arise as a consequence of
treatment with anti-angiogenic agents and can contribute to
tumour regrowth post therapy62. Consequently, the ability of
hypoxic cells to stimulate tumour initiation—either in naive
metastases or following therapy of primary tumours—is
considered to play a large role in treatment outcome. It may be
possible to interfere with the epigenetic regulation of DICER
during hypoxia and/or its inﬂuence on the expression of key
miRNAs that promote these adverse clinical effects. Recent
potent, orally available inhibitors of EZH2 have been
reported63,64 and our results suggest that treatment with these
agents induce DICER expression. Alternatively, an siRNA and/or
miRNA strategy that does not rely on Drosha/Dicer processing
and is not compromised within the tumour microenvironment
could be applied. Effective delivery of siRNA and/or miRNA
in vivo has improved remarkably and pre-clinical studies have
demonstrated the potential of miR-200b delivery in breast,
ovarian and other orthotopic models65.
Methods
Data set analyses. Retrieval and processing of breast cancer data sets. Pre-
processing of raw mRNA abundance data sets was performed in R statistical
environment (v2.14.1). Raw affymetrix-based data (PMIDs: 16273092, 17545524,
16141321, 16280042, 16478745, 18498629, 17157792, 19421193, 20098429,
20064235, 20490655, 20697068, 18821012, 18593943, 15721472, 21501481,
17079448, 21422418 and 21558518) were normalized using RMA (robust multi-
array average) algorithm66 (R package: affy v1.32.1). ProbeSet annotation to Entrez
Gene IDs was performed using custom CDFs67 (R packages: hgu133ahsentrezgcdf
v15.0.0, hgu133bhsentrezgcdf v15.0.0, hgu133plus2hsentrezgcdf v15.0.0,
hthgu133ahsentrezgcdf v15.0.0 and hgu95av2hsentrezgcdf v15.0.0 for affymetrix-
based breast cancer data sets). The METABRIC breast cancer data set was
preprocessed, summarized and quantile-normalized from the raw expression ﬁles
generated by Illumina BeadStudio (R packages: beadarray v2.4.2 and
illuminaHuman v3.db_1.12.2). Raw data ﬁles were downloaded from European
genome-phenome archive (EGA) (Study ID: EGAS00000000083). Data ﬁles of one
sample were not available at the time of this analysis and were therefore excluded.
All data sets were normalized independently. Preprocessed segmented genome
copy number aberration (CNA) data from the METABRIC cohort was downloaded
from EGA. Preprocessed mRNA abundance data from TCGA were downloaded
from cBioPortal for Cancer Genomics of Memorial Sloan-Kettering Cancer Center
http://www.cbioportal.org/public-portal/ on 6 November 2012. Level 4 processed
CNA data from TCGA were downloaded from GISTIC2 from the Broad Institute
at http://gdac.broadinstitute.org/runs/analyses__2012_09_13/reports/cancer/
BRCA/copynumber/gistic2/nozzle.html Discrete ampliﬁcation and deletion calls
for each sample based on the obtained CNA data were tabulated. For both mRNA
abundance and CNA data, patient clinical information were obtained online from
the original publication35.
Calculation of Winter signature scores. For each gene in the Winter signature,
each patient in a given cohort was assigned an initial score of either þ 1 or  1 as
follows: a patient was assigned þ 1 if her expression of that gene exceeded the
median expression of that gene in that complete cohort. Otherwise, the patient was
assigned  1 for that gene. For each patient in a given cohort, the þ 1’s and  1’s
obtained as described above over all genes in the Winter signature were summed and
the resulting sum was the Winter signature score for that patient in that cohort.
mRNA abundance correlation of Dicer with MITF or TP63. For each of the
Metabric (Training and Validation datasets combined) and TCGA breast cancer
mRNA abundance data sets, a scatter plot was generated of the Dicer mRNA
abundance against that of MITF. Pearson’s product–moment correlation
coefﬁcient of the mRNA abundance of the two genes was computed and its
P-value, based on the two-sided t-test for the Pearson’s product–moment
correlation, was computed. This analysis was repeated for the correlation of Dicer
mRNA abundance and TP63 mRNA abundance.
Comparison of Dicer mRNA abundance and Winter signature. For each of the
Metabric (Training and Validation datasets combined) and TCGA breast cancer
data sets, only patients with no Dicer copy number variation and those
with monoallelic Dicer loss were retained. These retained patients were then
divided into ﬁve groups as follows: those with monoallelic Dicer loss formed one
group, and those with no Dicer copy number variation were ordered by their Winter
signature scores and divided into four quarters, with the ﬁrst quarter comprising
patients with the lowest Winter signature scores, while the fourth represents those
with highest Winter signature scores. A strip plot was generated to visualize the
differences in Dicer mRNA abundance levels among these ﬁve groups. The Dicer
mRNA abundance of patients in each of the four quarters of the group with no Dicer
copy number variation was compared against the group with monoallelic Dicer loss,
by computing the P-value based on the Wilcoxon rank sum test.
Comparison of miR-103/107 expression and Winter signature. Analyses were
carried out in R statistical environment (version 3.0.1) (http:///www.r-project.org/).
All tests were two-sided and considered statistically signiﬁcant at the 0.05 level.
Clinical and miRNA expression were downloaded from the Cancer Genome Atlas
Project (TCGA) available through the associated ﬁles of the paper: ‘Comprehensive
molecular portraits of human breast tumors, Nature, 27 September 2012’ (https://
tcga-data.nci.nih.gov/docs/publications/brca_2012/). We also downloaded Level 3
(RNASeqV2) genes proﬁles for Breast Invasive Carcinoma from TCGA Data
Portal: https://tcga-data.nci.nih.gov/tcga/. A hypoxia score was assigned to each
TCGA sample based on the Winter hypoxia metagene signature and following the
previously reported methodology68. The Shapiro–Wilk test was applied to verify
whether the data follows a normal distribution. Accordingly, an analysis of variance
test with Tukey post-hoc test was applied to assess the relationship between miR-
103 and Winter hypoxia score, whereas a non-parametric test Kruskal–Wallis test
with Nemenyi post-hoc test was applied to assess the relationship between miR-107
expression and Winter hypoxia score.
Cell culture and treatment. The following cell lines were obtained from ATCC
and grown according to provided subculturing instructions: MCF7, MDA-MB-468,
MDA-MB-231, T47D, U373, HCT116, Hela, ME180 and SiHa. HCC1954 and
SUM149 cell lines were provided as a gift by Dr Benjamin Neel (Princess Margaret
Cancer Centre). HCC1954 cells were grown in RPMI medium supplemented with
10% fetal bovine serum (FBS) and SUM149 cells were grown in Ham’s F12
medium supplemented with 5% FBS, insulin (5 mgml 1), hydrocortisone
(1 mgml 1) and 10mM Hepes (pH 7.4). HMLER cells were a gift from Dr Robert
Weinberg (MIT) and were grown as previously described69. MCF10A cells were
provided by Dr Senthil Muthuswamy (Princess Margaret Cancer Centre) and were
grown in DMEM/F12 (Gibco BRL) supplemented with 5% donor horse serum,
20 ngml 1 epidermal growth factor, 10 mgml 1 insulin, 1 ngml 1 cholera toxin,
100 mgml 1 hydrocortisone, 50 mgml 1 penicillin and 50mgml 1 streptomycin.
Wild type and HIF1a / mouse embryonic ﬁbrobasts, RCC4 and
RCC4þ pVHL were grown in DMEM medium supplemented with 10% FBS. All
cell lines were routinely tested to conﬁrm the absence of Mycoplasma. For hypoxic
exposure, cells were transferred into a HypOxygen H35 workstation. The
atmosphere in the chamber consisted of 5% H2, 5% CO2, the desired % O2 and
residual N2. For protein stability experiments, MCF7 cells were exposed to
100 mgml 1 cycloheximide (Sigma) for 0, 2, 4 or 8 h of normoxia or 0.2% O2
hypoxia. For exposure to stress-inducing agents, indicated cell lines were grown for
24 h in 250mM CoCl2, 500mM DFO or 500 mM DMOG. For inhibition of KDM6A/
B activity, MCF7 and HMLER cells were grown for 24 h in GSK-J4 at indicated
concentrations. For inhibition of EZH2 activity, MCF7 and HMLER cells were
grown for 48–72 h in UNC1999 or GSK343 at indicated concentrations. For
exposure to TGFb1, HMLER cells were cultured in standard growth medium with
the addition of 5% FBS and treated with 2.5 ngml 1 TGFb1 for 12 days.
RNA extraction and quantitative reverse–transcription PCR. RNA was isolated
using TRI reagent (Sigma) and samples were reverse transcribed using qScript
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cDNA SuperMix (Quantas). Quantitative real-time PCR was performed on an
Eppendorf Realplex2 mastercycler using SYBR green (Quantas). Speciﬁc primers
used are listed in Supplementary Table 2. For determination of DICER mRNA
half-life, cells were treated with 5 mgml 1 actinomycin D (Sigma) for the indicated
times. De novo RNA synthesis was measured using the Click-iT Nascent RNA
Capture Kit (Molecular Probes). Brieﬂy, MCF7 and HMLER cells were pulse
labelled with 0.2mM 5-ethynyl Uridine for 1 h during aerobic conditions or 24 h
hypoxia (0.2% O2) after which RNA was isolated as described above. Nascent RNA
was captured using magnetic streptavidin beads, reverse transcribed and analysed
by quantitative real-time PCR. For determination of pri-miRNA and mature
miRNA levels, the following assays from Applied Biosystems were used: pri-
miR200a (Hs03303376_pri), pri-miR200b (Hs03303027_pri), pri-miR429
(Hs03303727_pri), pri-miR200c (Hs03303157_pri), pri-miR141 (Hs03303157_pri),
pri-miR210 (Hs03302948_pri), hsa-miR200a (000502), hsa-miR200b (002251),
hsa-miR429 (001024), hsa-miR200c (002300), miR141 (002145), hsa-miR103
(000439), hsa-miR107 (000443), hsa-miR210 (000512), RNU44 (001094) and
RNU48 (001006).
Western blot analysis. Cells were washed twice with cold PBS and scraped in
50mM Tris HCl pH 8.0, 150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate and
0.1% SDS supplemented with protease and phosphatase inhibitors (Roche). After
centrifugation at 10,000 g, supernatants were boiled in Laemmli buffer for 10min
and proteins were resolved by SDS–PAGE. Proteins were subsequently transferred
onto polyvinylidene diﬂuoride membrane and blocked for 1 h in TBS containing
0.05% Tween 20 (TBS-T) supplemented with 5% skim milk powder. Membranes
were probed overnight at 4 C with antibodies directed against: DICER (1:200,
H-212; Santa Cruz Biotechnology), CA9 (1:1,000, M75; gift from Dr Silvia Pas-
torekova), H3K27me3 (1:20,000, 07-449; Upstate), H3 (1:5,000, D1H2; Cell Sig-
naling Technology), E-cadherin (1:1,000, Cell Signaling Technology), Vimentin
(1:500, clone V9; Sigma), b-tubulin (1:20,000, Abcam), b-actin (1:20,000, Sigma) or
eIF4E (1:1,000, BD Transduction Laboratories). Bound antibodies were visualized
using horseradish peroxidase-linked secondary antibodies (GE Healthcare) and
ECL luminescence (Pierce).
Luciferase reporter assay. A 2.5-kb fragment from the 50-ﬂanking region of the
DICER1 gene was previously described15. MCF7 cells were transiently co-
transfected with the DICER or CA9 promoter70 constructs and pcDNALacZ using
Lipofectamine (Invitrogen). Transfected cells were subcultured 16 h post
transfection, exposed to hypoxia and ﬁnally harvested 48 h after transfection.
Luciferase and b-galactosidase activity was measured using a commercial kit
(Applied Biosystems) and measured on the Fluorstar Optima plate reader (BMG
Labtech).
Plasmids and viral infections. Knockdown was achieved using lentiviral shRNA
constructs directed against DICER: TRCN0000004386, TRCN000000439; HIF-1a:
TRCN0000003810; KDM6A: TRCN0000107760; KDM6B: TRCN0000236677;
green ﬂuorescent protein as control: TRCN0000072181. DICER open reading
frame was cloned into pLenti CMV DEST using Gateway LR Clonase II (Invi-
trogen). Pri-miR200b was cloned into pLJM1 as Age1/EcoR1 fragment. Lentiviral
particles were generated by co-transfection of 293T cells with packaging plasmids
pCMVdR8.74psPAX2 and pMD2.G, together with shRNA vector pLKO.1 using
Lipofectamine 2000. Virus supernatant was harvested 48 and 72 h post transfec-
tion. Cell lines were transduced with lentiviral supernatant in the presence of
8 mgml 1 polybrene. Infected cells were selected for 48 h in 2 mgml 1 puromycin-
containing media or 7 days in 5 mgml 1 blasticidin-containing media. Validated
siRNA duplexes directed against EZH2 (ref. 52) 50-AAGACTCTGAATGCAGTT
GCT-30 and HIF1a 50-CUGAUGACCAGCAACUUGA-30 were ordered from
Sigma. Stealth RNA interference-negative control was ordered from Invitrogen
(12935-300). For siRNA experiments, cells were transfected 72 h before analysis
with 2 nM siRNA duplex using Lipofectamine (Invitrogen).
Chromatin immunoprecipitation. MCF7 and HMLER cells were ﬁxed in 1%
formaldehyde. Cross-linking was allowed to proceed for 10min at room tem-
perature and stopped by addition of glycine at a ﬁnal concentration of 0.125M,
followed by an additional incubation for 5min. Fixed cells were washed twice with
PBS and harvested in SDS buffer (50mM Tris at pH 8.1, 0.5% SDS, 100mM NaCl,
5mM EDTA), supplemented with protease inhibitors (Aprotinin, Antipain and
Leupeptin all at 5 mgml 1 and 1mM phenylmethylsulfonyl ﬂuoride). Cells were
pelleted by centrifugation and suspended in IP Buffer (100mM Tris at pH 8.6,
100mM NaCl, 0.3% SDS, 1.7% Triton X-100 and 5mM EDTA), containing pro-
tease inhibitors. Cells were disrupted by sonication, yielding genomic DNA frag-
ments with a bulk size of 200–500 bp. For each immunoprecipitation, 1ml of lysate
was precleared by addition of 35 ml of blocked protein A beads (50% slurry protein
A-Sepharose (Amersham); 0.5mgml 1 fatty acid-free BSA (Sigma); and
0.2mgml 1 herring sperm DNA in TE), followed by clariﬁcation by centrifuga-
tion. Ten-microlitre aliquots of precleared suspension were reserved as input DNA
and kept at 4 C. Samples were immunoprecipitated overnight at 4 C using 1 mg of
antibodies for either HA as a negative control (sc-805; Santa Cruz), H3K27me3
(07-449; Upstate), EZH2 (AC22, Millipore), KDM6A (ab36938, Abcam) or
KDM6B (ab85392, Abcam). Immune complexes were recovered by adding 40 ml of
blocked protein A beads and incubated for 4 h at 4 C. Beads were washed three
times in 1ml of Mixed Micelle Buffer (20mM Tris at pH 8.1, 150mM NaCl, 5mM
EDTA, 5% w/v sucrose, 1% Triton X-100 and 0.2% SDS), twice in 1ml of Buffer
500 (50mM HEPES at pH 7.5, 0.1% w/v deoxycholic acid, 1% Triton X-100 and
1mM EDTA), twice in 1ml of LiCl Detergent Wash Buffer (10mM Tris at pH 8.0,
0.5% deoxycholic acid, 0.5% NP-40, 250mM LiCl and 1mM EDTA) and once in
1ml of TE. Immunocomplexes were eluted from beads in 250 ml elution buffer (1%
SDS and 0.1M NaHCO3) for 2 h at 65 C with continuous shaking at 1,000 r.p.m.,
and after centrifugation supernatants were collected. Two hundred and ﬁfty
microlitres elution buffer was added to input DNA samples and these were pro-
cessed in parallel with eluted samples. Cross-links were reversed overnight at 65 C
followed by a 2-h digestion with RNAseA at 37 C and 2 h proteinase K
(0.2 mgml 1) at 55 C. DNA fragments were recovered using QIAquick PCR
puriﬁcation columns, according to manufacturers’ instructions. Samples were
eluted in 75 ml EB buffer and then further 1/5 diluted in TE buffer. The immu-
noprecipitated DNA was quantiﬁed by real-time qPCR using SYBR Green I
(Applied Biosystems) and following forward and reverse primers: DICER: F-50-CG
GTGGGCGTTAAATAAGTG-30 and R-50-CCCCCATACTGAGATGCTGT-30 .
After PCR, melting curves were acquired to ensure that a single product was
ampliﬁed in the reaction.
Global miRNA proﬁling. Total RNA was isolated from cells bearing shDICER
G6 and pLKO.1 as control or cells exposed to hypoxia, and samples were
subjected to Nanostring analysis using the Nanostring Human v2 miRNA code set
at the UHN Microarray Centre. miRNAs with counts equal or lower than
the negative controls were discarded from the analysis. miRNA counts were
normalized to housekeeping gene RPLP0 and averaged for three independent
experiments.
Fluorescence-activated cell sorting. FACS analysis was performed on a BD
FACS Calibur (Becton Dickinson) using PE-conjugated anti-CD24 antibody (clone
ML5) and APC-conjugated anti-CD44 (clone G44-26) (BD Bioscience).
Mammosphere culture. Mammosphere culture was performed as previously
described71, with slight modiﬁcations. The mammospheres were cultured for 7–10
days in MammoCult media (StemCell Technologies) supplemented with 4 mgml 1
heparin (Sigma) and 0.5 mgml 1 hydrocortisone (Sigma). For sphere formation
assays, mammospheres were dissociated to single cells with trypsin and 500
dissociated cells were plated in a 96-well plate and cultured for 10 days.
Mammospheres with diameter 475mm were counted.
In vivo models. All animal experiments were performed under protocols approved
by the Ontario Cancer Institute’s Animal Care Committee, according the regula-
tions of the Canadian Council on Animal Care. Female NOD-SCID mice at 6–8
weeks old were used to inject HMLER cells into the inguinal mammary fat pad
(1 106 cells in a 1:1 mixture of BD Matrigel and media) following anaes-
thetization with isoﬂurane. One week before the injection of cells, a 60-day release
pellet containing 2mg 17b-estradiol and 20mg progesterone (Innovative Research
of America) was implanted subcutaneously into each mouse. At end point, mice
were sacriﬁced, tumours harvested and optical coherence tomography embedded
for immunohistochemical staining and analysis.
Immunohistochemical staining and image analysis. The expression of CD44
and EF5 in orthotopic xenografts was investigated as follows: Flash-frozen tissue
samples were embedded in optical coherence tomography and stored at  80 C
until sectioned. Sections were thawed at room temperature before ﬁxation in 2%
paraformaldehyde for 20min. After washing sections in PBS, sections were per-
meabilized in PBS containing 0.5% Triton X-100 for 15min, wash 3 5min in
PBS-T and then incubated in a primary antibody cocktail of mouse anti-human
CD44 (1:75, BD Pharmingen) and rat anti-mouse CD31 (1:300, BD Pharmingen)
or anti-human H3K27me3 (1:500, C36B11; Cell Signalling) overnight at room
temperature. Sections were subsequently washed 3 5min in PBS-T followed by
incubation in a secondary antibody cocktail of goat anti-mouse Alexaﬂuor 488
(1:200, Life Technologies) and goat anti-rat Alexaﬂuor 555 (1:200, Life technolo-
gies) or goat anti-mouse Alexaﬂuor 488 (1:200, Life Technologies) for 1 h at room
temperature. After washing in PBS-T, sections were incubated in EF5-Cy5 (1:50,
provided by Dr Cameron Koch) for 3 h at room temperature. After washing,
sections were ﬁnally incubated in a working solution of DAPI (4,6-diamidino-2-
phenylindole) for 5min, washed, dried and imaged on a laser scanning microscope
(Huron Technologies). Images were analysed using Deﬁniens Tissue Studio soft-
ware, which allows for semi-automatic histology image analysis. Brieﬂy, the soft-
ware was trained to identify viable tumour areas, necrotic areas, tumour stroma
and empty areas within the scanned section. A threshold was determined by mean
þ 2 s.d. intensity in the EF5 and CD44 channels. The average CD44 staining
intensity within the tumour area was measured in both EF5-negative and -positive
areas. EF5-positive area above a background threshold was obtained from the
average intensity of all tumour sections.
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Statistical analyses. Unless otherwise stated, a Student’s t-test or one-way ana-
lysis of variance with Bonferroni’s post-hoc test were used to test signiﬁcance
between populations. A signiﬁcance threshold of Po0.05 was applied. Points and
error bars plotted in graphs represent the mean±s.e.m for three or more inde-
pendent experiments.
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